# Progyny Inc. (PGNY) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Health Care Providers. Price $29.06, market value $2.2 billion.

## Valuation
- **P/E (trailing): 31.6×** (5-yr avg 62.0×, 3-yr avg 43.2×). Progyny Inc. trades at 31.6× trailing earnings, well below its own five-year average of 62.0×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 12.6×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.90**. A PEG of 0.90 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.7×**. Each dollar of revenue is priced at 1.7×.
- **Price / book: 4.9×**. The shares trade at 4.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 8.0%** (5-yr avg 5.4%). Free cash flow equals 8.0% of the market value, above its five-year average of 5.4%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 3.2%**. The inverse of the P/E: 3.2% of the price is earned each year.

## Profitability
- **Gross margin: 24.6%**. Progyny Inc. keeps 24.6% of revenue after the direct cost of what it sells, a thin margin typical of retail, distribution and commodity businesses.
- **Operating margin: 8.6%**. 8.6% of revenue is left after running the business.
- **Net margin: 4.5%**. 4.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 11.3%**. 11.3% on shareholders' equity is solid.
- **Return on assets: 10.6%**. Each dollar of assets produces 10.6% of profit.

## Growth
- **Revenue growth (1 yr): 10.4%** (3-yr 17.9%/yr, 5-yr 30.2%/yr). Revenue grew 10.4% over the last year, against 30.2% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 14.0%** (3-yr 29.4%/yr, 5-yr 6.7%/yr). Earnings per share rose 14.0%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 35.5%/yr**. Free cash flow has compounded at 35.5% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Current ratio: 2.73** (quick 2.73). Current assets cover the next year's liabilities 2.73 times.
- **Altman Z-score: 9.56**. A Z-score of 9.56 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Progyny Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Progyny Inc.; the consensus is strong_buy, with an average price target of $34.42 (+18% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 57.2%** (YTD 14.5%, 3-mo -6.7%). The shares are up 57.2% over twelve months including dividends.
- **From 52-week high: -12.1%** (80.5% above the low). Trading 12% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 63**. An RSI of 63 is neutral.
- **Beta (1 yr): 0.27** (volatility 54%). Beta of 0.27 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PGNY · Page: https://foliofundamentals.com/stocks/pgny

Not investment advice.